$4.30
0.081.78%
Pre-Market: 7:57 PM EDT
15 minutes delayed
PDS Biotechnology
PDSBNASDAQ
want to know what
the Bulls & Bears Say?
PDS Biotechnology (NASDAQ:PDSB) Stock, Analyst Ratings, Price Targets, Forecasts
PDS Biotechnology Corp has a consensus price target of $16.5 based on the ratings of 5 analysts. The high is $21 issued by HC Wainwright & Co. on June 12, 2024. The low is $9 issued by B. Riley Securities on June 12, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B. Riley Securities, and HC Wainwright & Co. on June 12, 2024, June 12, 2024, and May 15, 2024, respectively. With an average price target of $17 between HC Wainwright & Co., B. Riley Securities, and HC Wainwright & Co., there's an implied 295.35% upside for PDS Biotechnology Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B. Riley Securities
Oppenheimer
Chardan Capital
1calculated from analyst ratings
Analyst Ratings for PDS Biotechnology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2024 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2024 | Buy Now | 109.3% | B. Riley Securities | Kalpit Patel | $11 → $9 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 03/28/2024 | Buy Now | 155.81% | B. Riley Securities | Kalpit Patel | $14 → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | $21 → $21 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 365.12% | Oppenheimer | Leland Gershell | $23 → $20 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | Buy Now | 458.14% | Oppenheimer | Leland Gershell | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 05/26/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 458.14% | Oppenheimer | Leland Gershell | → $24 | Reiterates | → Outperform | Get Alert |
| 04/24/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 179.07% | B. Riley Securities | Kalpit Patel | → $12 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Maintains | Buy | Get Alert |
| 01/03/2023 | Buy Now | 388.37% | HC Wainwright & Co. | Joseph Pantginis | $15 → $21 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 272.09% | Chardan Capital | Geulah Livshits | $15 → $16 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 132.56% | B. Riley Securities | Kalpit Patel | → $10 | Initiates | → Buy | Get Alert |
| 08/12/2021 | Buy Now | 248.84% | HC Wainwright & Co. | Joseph Pantginis | $20 → $15 | Maintains | Buy | Get Alert |
FAQ
What is the target price for PDS Biotechnology (PDSB) stock?
The latest price target for PDS Biotechnology (NASDAQ:PDSB) was reported by HC Wainwright & Co. on June 12, 2024. The analyst firm set a price target for $21.00 expecting PDSB to rise to within 12 months (a possible 388.37% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PDS Biotechnology (PDSB)?
The latest analyst rating for PDS Biotechnology (NASDAQ:PDSB) was provided by HC Wainwright & Co., and PDS Biotechnology reiterated their buy rating.
When was the last upgrade for PDS Biotechnology (PDSB)?
There is no last upgrade for PDS Biotechnology
When was the last downgrade for PDS Biotechnology (PDSB)?
There is no last downgrade for PDS Biotechnology.
When is the next analyst rating going to be posted or updated for PDS Biotechnology (PDSB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PDS Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PDS Biotechnology was filed on June 12, 2024 so you should expect the next rating to be made available sometime around June 12, 2025.
Is the Analyst Rating PDS Biotechnology (PDSB) correct?
While ratings are subjective and will change, the latest PDS Biotechnology (PDSB) rating was a reiterated with a price target of $21.00 to $21.00. The current price PDS Biotechnology (PDSB) is trading at is $4.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.